Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

Illumina to scale-up philanthropic sequencing with $120M investment

Company plans to reach tens of thousands of patients per year by partnering with non-profit Genetic Alliance

By Richard Guy, Biopharma Analyst
November 23, 2021 11:47 PM UTC

Seeking the most efficient path to scale its philanthropic sequencing from a few hundred patients per year to tens of thousands, Illumina has decided to hand off operations to its new partner, the non-profit Genetic Alliance.

“We’ve been running this pilot for eight years. We want to reach more patients, and we think now is the time to do that.” Ryan Taft told BioCentury. Taft is VP of scientific research at  Illumina Inc. (NASDAQ:ILMN) and the company’s iHope lead. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Illumina Inc.